When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DCPH - Deciphera Presses Forward Towards NDA Filing After Positive Data And Large Cash Raise
Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals (DCPH) announced that it had achieved positive results in a phase 3 study, using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to file its very first NDA in this patient population in Q1 of 2020. The company reported that it had met on the primary endpoint of progression-free survival, which should be good enough for FDA approval. Additional detailed results from this late-stage study will be revealed at an upcoming medical meeting.